Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.